Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biohaven Ltd.BHVN · Entity 4379 | Director | April 28, 2026 | May 01, 2026 |
| Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269 | Director | October 03, 2022 | October 03, 2022 |
| CELGENE CORP /DE/CELG · Entity 15781 | Director · see remarks | December 31, 2017 | January 31, 2018 |
| Chubb LtdCB · Entity 1639 | Director | May 21, 2026 | May 26, 2026 |
| DANAHER CORP /DE/DHR · Entity 2871 | Director | May 15, 2017 | May 17, 2017 |
| MEDICINES CO /DEMDCO · Entity 152552 | Director | November 09, 2017 | November 13, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biohaven Ltd.
Report date April 28, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28 | Direct | 68,693 |
Reported balance
After 2026-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693 F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Biohaven Pharmaceutical Holding Co Ltd.
Report date October 03, 2022 · Filed October 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 2,900 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| Restricted Share Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-03 · Disposition to issuer · Disposed 3,417 · Balance 0 F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.17 · Expires 2031-05-05 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-10-03 · Disposition to issuer · Disposed 11,996 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.88 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-10-03 · Disposition to issuer · Disposed 18,948 · Balance 0 F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").
F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").
F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.
F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.
CELGENE CORP /DE/
Report date December 31, 2017 · Filed January 31, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,015,106 |
Reported balance
After 2017-09-07 transaction · row 1
1 source rowRow 1 · 2017-09-07 · Gift · Disposed 45,000 · Balance 1,015,106 F1: Gift to a family foundation of which Mr. Hugin is a trustee, but he is not deemed to hold a pecuniary interest in the foundation. |
| Common StockSEC Table I · non-derivative | IndirectBy Children | 9,600 |
Reported balance
Holding disclosure · report date 2017-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 9,600 F2: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Indirect401(k) Plan | 641 |
Reported balance
Holding disclosure · report date 2017-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 641 |
Filing footnotes · ownership attribution and instrument terms
F1: Gift to a family foundation of which Mr. Hugin is a trustee, but he is not deemed to hold a pecuniary interest in the foundation.
F2: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Chubb Ltd
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 21,626 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 1,135 · Balance 21,626 F1: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. |
| Common SharesSEC Table I · non-derivative | IndirectBy Son | 225 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 225 F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common SharesSEC Table I · non-derivative | IndirectBy Son | 110 |
Reported balance
Holding disclosure · report date 2026-05-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 110 F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date.
F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
DANAHER CORP /DE/
Report date May 15, 2017 · Filed May 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,576 |
Reported balance
After 2017-05-15 transaction · row 1
1 source rowRow 1 · 2017-05-15 · Grant · Acquired 990 · Balance 3,576 F1: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The RSUs vest on the earlier of the first anniversary of the grant date, or the date of (and immediately prior to) the next annual meeting of Danaher's shareholders following the grant date, but the underlying shares are not issued until the earlier of the director's death or the first day of the seventh month following the director's retirement from the Board. |
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $83.28 · Expires 2027-05-15 | Direct | 3,540 |
Reported balance
After 2017-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-05-15 · Grant · Acquired 3,540 · Balance 3,540 |
Filing footnotes · ownership attribution and instrument terms
F1: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. The RSUs vest on the earlier of the first anniversary of the grant date, or the date of (and immediately prior to) the next annual meeting of Danaher's shareholders following the grant date, but the underlying shares are not issued until the earlier of the director's death or the first day of the seventh month following the director's retirement from the Board.
MEDICINES CO /DE
Report date November 09, 2017 · Filed November 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 163,431 |
Ending reported balance
After 2017-11-09 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2017-11-09 · Exercise / conversion · Acquired 7,500 · Balance 123,133 Row 2 · 2017-11-09 · Exercise / conversion · Acquired 7,500 · Balance 130,633 Row 3 · 2017-11-09 · Exercise / conversion · Acquired 7,500 · Balance 138,133 Row 4 · 2017-11-09 · Exercise / conversion · Acquired 13,259 · Balance 151,392 Row 5 · 2017-11-09 · Exercise / conversion · Acquired 12,039 · Balance 163,431 |
| Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.30 · Expires 2018-05-29 | Direct | 0 |
Reported balance
After 2017-11-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-11-09 · Exercise / conversion · Disposed 7,500 · Balance 0 F6: Not applicable F1: This option vested in twelve equal monthly installments beginning on June 29, 2008. |
| Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2019-05-28 | Direct | 0 |
Reported balance
After 2017-11-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-11-09 · Exercise / conversion · Disposed 7,500 · Balance 0 F6: Not applicable F2: This option vested in twelve equal monthly installments beginning on June 28, 2009. |
| Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.28 · Expires 2020-06-02 | Direct | 0 |
Reported balance
After 2017-11-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-11-09 · Exercise / conversion · Disposed 7,500 · Balance 0 F6: Not applicable F3: This option vested in twelve equal monthly installments beginning on July 2, 2010. |
| Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.18 · Expires 2021-05-26 | Direct | 0 |
Reported balance
After 2017-11-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-11-09 · Exercise / conversion · Disposed 13,259 · Balance 0 F6: Not applicable F4: This option vested in one installment beginning on June 26, 2011. |
| Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.14 · Expires 2022-05-22 | Direct | 0 |
Reported balance
After 2017-11-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-11-09 · Exercise / conversion · Disposed 12,039 · Balance 0 F6: Not applicable F5: This option vested in one installment beginning on June 22, 2012. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vested in twelve equal monthly installments beginning on June 29, 2008.
F2: This option vested in twelve equal monthly installments beginning on June 28, 2009.
F3: This option vested in twelve equal monthly installments beginning on July 2, 2010.
F4: This option vested in one installment beginning on June 26, 2011.
F5: This option vested in one installment beginning on June 22, 2012.
F6: Not applicable
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Allergan plc
Report date May 08, 2020 · Filed May 12, 2020
Section 16 reporting ended · disclosed 2020-05-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-05-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-08 · Disposition to issuer · Disposed 4,294 · Balance 0 F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 20:20 UTC | Chubb Ltd CB · Entity 1639 | GrantCommon Shares | 1,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-239385 · ownership.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,626 F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. Read SEC document |
| April 28, 2026 Filed May 1, 2026 00:07 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 68,693 | $0.00 Strike: $9.61 | $0.00 |
DisclosureSEC source: 0001232505-26-000003 · wk-form4_1777594053.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,693 Underlying: Common Shares · 68,693 shares Expires 2036-04-28 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| May 15, 2025 Filed May 16, 2025 22:51 UTC | Chubb Ltd CB · Entity 1639 | GrantCommon Shares | 1,284 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-25-045003 · ownership.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,491 F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. Read SEC document |
| May 05, 2025 Filed May 7, 2025 21:11 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to buy) · Derivative | 31,716 | $0.00 Strike: $22.62 | $0.00 |
DisclosureSEC source: 0001935979-25-000041 · wk-form4_1746652311.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,716 Underlying: Common Shares · 31,716 shares Expires 2035-05-05 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2026 or (b) the date of the 2026 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| May 16, 2024 Filed May 17, 2024 16:53 UTC | Chubb Ltd CB · Entity 1639 | GrantCommon Shares | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-044606 · marketforms-65942.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,207 F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan, which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan, which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. Read SEC document |
| April 30, 2024 Filed May 2, 2024 23:33 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Option (Right to Buy) · Derivative | 16,592 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001562180-24-003752 · primarydocument.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,592 Underlying: Common Shares · 16,592 shares Expires 2034-04-30 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| May 17, 2023 Filed May 19, 2023 14:00 UTC | Chubb Ltd CB · Entity 1639 | GrantCommon Shares | 1,634 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-030878 · doc4.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,980 F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan, which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan, which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. Read SEC document |
| May 02, 2023 Filed May 4, 2023 21:51 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Option (Right to Buy) · Derivative | 52,906 | $0.00 Strike: $13.20 | $0.00 |
DisclosureSEC source: 0001562180-23-003940 · primarydocument.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,906 Underlying: Common Shares · 52,906 shares Expires 2033-05-02 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 2, 2024 or (b) the date of the 2024 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:25 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 18,948 | Not disclosed Strike: $66.88 | Not disclosed |
DisclosureSEC source: 0001562180-22-006961 · primarydocument.xml · derivative · entry 5 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 18,948 shares Expires 2030-06-09 F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:25 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 11,996 | Not disclosed Strike: $70.17 | Not disclosed |
DisclosureSEC source: 0001562180-22-006961 · primarydocument.xml · derivative · entry 4 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 11,996 shares Expires 2031-05-05 F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:25 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerStock Options (Right to Buy) · Derivative | 8,239 | Not disclosed Strike: $95.33 | Not disclosed |
DisclosureSEC source: 0001562180-22-006961 · primarydocument.xml · derivative · entry 3 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,239 shares Expires 2032-04-28 F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:25 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerRestricted Share Unit Award · Derivative | 3,417 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-006961 · primarydocument.xml · derivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,417 shares Expires not disclosed F1 · derivative.exercise_price: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F3 · derivative.exercise_price: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. F3 · shares: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. F3 · price: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. F3 · derivative.exercise_date: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. F3 · derivative.expiration_date: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes. Read SEC document |
| October 03, 2022 Filed Oct 3, 2022 20:25 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | Disposition to issuerCommon Shares | 2,900 | $148.50 | $430,650.00 |
DisclosureSEC source: 0001562180-22-006961 · primarydocument.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). F2 · price: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | GrantStock Options (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 13 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-10-04 F5 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionStock Options (Right to Buy) · Derivative | 9,474 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 12 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,474 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,998 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 11 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionStock Options (Right to Buy) · Derivative | 4,119 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 10 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 9,474 | Not disclosed Strike: $3.39 | Not disclosed |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 9 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,474 Underlying: Common Shares · 9,474 shares Expires 2030-06-09 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 5,998 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 8 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,998 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherStock Options (Right to Buy) · Derivative | 4,119 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 7 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,119 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | Tax withholdingCommon Shares | 3,263 | $7.50 | $24,472.50 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 6 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,486 F3 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 9,474 | $3.39 | $32,116.86 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 5 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 5,998 | $3.56 | $21,352.88 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 4 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | Exercise / conversionCommon Shares | 4,119 | $4.84 | $19,935.96 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 3 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 1,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,158 F2 · shares: Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC | Biohaven Ltd. BHVN · Entity 4379 | OtherCommon Shares | 1,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,450 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). Read SEC document |
| October 03, 2022 Filed Oct 12, 2022 22:31 UTC Amendment | Biohaven Ltd. BHVN · Entity 4379 | Tax withholdingCommon Shares | 12,959 | $7.50 | $97,192.50 |
DisclosureSEC source: 0001562180-22-007175 · primarydocument.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,959 F1 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options. F2 · shares: This amendment is being filed to correct the amount of shares beneficially owned reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that 3,263 shares were withheld by the Issuer in connection with the share settlement to cover the cost of the stock options; however, as reflected in this amendment, 9,790 shares were withheld by the Issuer in connect with the share settlement to cover the cost of the stock options. There were no other changes made to the information in the Original Form 4. Read SEC document |
| May 19, 2022 Filed May 23, 2022 16:55 UTC | Chubb Ltd CB · Entity 1639 | GrantCommon Shares | 1,594 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-031281 · doc4.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,346 F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 21:00 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 8,239 | $0.00 Strike: $97.74 | $0.00 |
DisclosureSEC source: 0001562180-22-003585 · primarydocument.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,239 Underlying: Common Shares · 8,239 shares Expires 2032-04-27 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2023 or (b) the date of the 2023 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 21:52 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantRestricted Share Unit Award · Derivative | 3,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-007870 · primarydocument.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,417 Underlying: Common Shares · 3,417 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the issuer. F1 · price: Each restricted share unit represents the contingent right to receive one common share of the issuer. F2 · derivative.exercise_date: The reporting person was granted 3,417 restricted share units on December 20, 2021, which vested immediately upon grant. These restricted share units will settle on a deferred basis upon the reporting person's retirement from the Board of Directors of the issuer. F3 · derivative.expiration_date: Not applicable. Read SEC document |
| May 20, 2021 Filed May 24, 2021 18:32 UTC | Chubb Ltd CB · Entity 1639 | GrantCommon Shares | 1,836 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-035243 · doc4.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,752 F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. Read SEC document |
| May 05, 2021 Filed May 7, 2021 16:33 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Option (Right to Buy) · Derivative | 11,996 | $0.00 Strike: $71.94 | $0.00 |
DisclosureSEC source: 0001562180-21-003335 · primarydocument.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,996 Underlying: Common Shares · 11,996 shares Expires 2031-05-04 F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2022 or (b) the date of the 2022 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| June 09, 2020 Filed Jun 12, 2020 17:58 UTC | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Options (Right to buy) · Derivative | 36,000 | $0.00 Strike: $68.57 | $0.00 |
DisclosureSEC source: 0001562180-20-004470 · primarydocument.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Shares · 36,000 shares Expires 2030-06-09 F1 · derivative.exercise_date: This option grant was made pursuant to the issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on June 9, 2020, 2021, and 2022, subject to the reporting person's continuous service with the issuer at each vesting date. Read SEC document |
| June 09, 2020 Filed Mar 26, 2021 16:14 UTC Amendment | Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 | GrantStock Options (Right to buy) · Derivative | 18,948 | $0.00 Strike: $68.57 | $0.00 |
DisclosureSEC source: 0001562180-21-002442 · primarydocument.xml · derivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,948 Underlying: Common Shares · 18,948 shares Expires 2030-06-09 F1 · shares: On June 12, 2020, the reporting person filed a Form 4 in respect of 36,000 options granted pursuant to the issuer's non-employee director compensation policy. The issuer subsequently determined that 17,052 of the options comprising such award were null and void upon grant as a result of the $1,000,000 annual limit for non-employee director compensation under its 2017 Equity Incentive Plan. F2 · derivative.exercise_date: This option grant was made pursuant to the issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on June 9, 2021, 2022, and 2023, subject to the reporting person's continuous service with the issuer at each vesting date. Read SEC document |
| May 20, 2020 Filed May 22, 2020 15:27 UTC | Chubb Ltd CB · Entity 1639 | GrantCommon Shares | 2,916 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-031598 · doc4.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,916 F1 · kind: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. F1 · price: Restricted stock award granted as director fees under a Chubb Limited long-term incentive plan (the "Plan"), which meets the requirements of Rule 16b-3. Such restricted stock will vest on the day of the next annual Chubb Limited shareholders meeting, assuming the reporting person is a director of Chubb Limited on such date. Read SEC document |
| May 08, 2020 Filed May 12, 2020 01:58 UTC | Allergan plc AGN · Entity 149298 | Disposition to issuerOrdinary Shares, par value $0.0001 | 4,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012762 · doc4.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · balance_after: Reflects the disposition of ordinary shares ("Allergan Shares") of Allergan plc ("Allergan") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. ("AbbVie"), Venice Subsidiary, LLC ("Acquirer Sub") and Allergan (the "Transaction Agreement"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the "Scheme"). In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share. Read SEC document |
| May 01, 2020 Filed May 5, 2020 00:55 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 2,064 | $189.74 | $391,623.36 |
DisclosureSEC source: 0001179110-20-005444 · edgar.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,294 Read SEC document |
| May 02, 2019 Filed May 2, 2019 20:48 UTC | Allergan plc AGN · Entity 149298 | GrantOrdinary Shares, par value $0.0001 | 2,064 | $145.33 | $299,961.12 |
DisclosureSEC source: 0001179110-19-005415 · edgar.xml · nonDerivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,285 F2 · shares: These restricted stock units shall vest on the earlier of (i) the day before the 2020 Annual General Meeting of Shareholders and (ii) May 1, 2020. F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| April 30, 2019 Filed May 2, 2019 20:48 UTC | Allergan plc AGN · Entity 149298 | Tax withholdingOrdinary Shares, par value $0.0001 | 205 | $147.00 | $30,135.00 |
DisclosureSEC source: 0001179110-19-005415 · edgar.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,221 F1 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 16:26 UTC | Allergan plc AGN · Entity 149298 | GrantOrdinary Shares, par value $0.0001 | 426 | $139.07 | $59,243.82 |
DisclosureSEC source: 0001179110-19-002128 · edgar.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,426 F1 · shares: These restricted stock units shall vest on the earlier of (i) the day before the 2019 Annual General Meeting of Shareholders and (ii) May 2, 2019. F2 · balance_after: Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:18 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionStock Option (right-to-buy) · Derivative | 12,039 | Not disclosed Strike: $21.14 | Not disclosed |
DisclosureSEC source: 0001179110-17-014063 · edgar.xml · derivative · entry 10 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,039 shares Expires 2022-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable F5 · derivative.exercise_date: This option vested in one installment beginning on June 22, 2012. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:18 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionStock Option (right-to-buy) · Derivative | 13,259 | Not disclosed Strike: $18.18 | Not disclosed |
DisclosureSEC source: 0001179110-17-014063 · edgar.xml · derivative · entry 9 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,259 shares Expires 2021-05-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable F4 · derivative.exercise_date: This option vested in one installment beginning on June 26, 2011. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:18 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionStock Option (right-to-buy) · Derivative | 7,500 | Not disclosed Strike: $8.28 | Not disclosed |
DisclosureSEC source: 0001179110-17-014063 · edgar.xml · derivative · entry 8 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2020-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable F3 · derivative.exercise_date: This option vested in twelve equal monthly installments beginning on July 2, 2010. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:18 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionStock Option (right-to-buy) · Derivative | 7,500 | Not disclosed Strike: $7.51 | Not disclosed |
DisclosureSEC source: 0001179110-17-014063 · edgar.xml · derivative · entry 7 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2019-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable F2 · derivative.exercise_date: This option vested in twelve equal monthly installments beginning on June 28, 2009. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:18 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionStock Option (right-to-buy) · Derivative | 7,500 | Not disclosed Strike: $18.30 | Not disclosed |
DisclosureSEC source: 0001179110-17-014063 · edgar.xml · derivative · entry 6 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2018-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · price: Not applicable F1 · derivative.exercise_date: This option vested in twelve equal monthly installments beginning on June 29, 2008. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:18 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionCommon Stock | 12,039 | $21.14 | $254,504.46 |
DisclosureSEC source: 0001179110-17-014063 · edgar.xml · nonDerivative · entry 5 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:18 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionCommon Stock | 13,259 | $18.18 | $241,048.62 |
DisclosureSEC source: 0001179110-17-014063 · edgar.xml · nonDerivative · entry 4 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:18 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionCommon Stock | 7,500 | $8.28 | $62,100.00 |
DisclosureSEC source: 0001179110-17-014063 · edgar.xml · nonDerivative · entry 3 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:18 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionCommon Stock | 7,500 | $7.51 | $56,325.00 |
DisclosureSEC source: 0001179110-17-014063 · edgar.xml · nonDerivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 18:18 UTC | MEDICINES CO /DE MDCO · Entity 152552 | Exercise / conversionCommon Stock | 7,500 | $18.30 | $137,250.00 |
DisclosureSEC source: 0001179110-17-014063 · edgar.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.